Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease

Phase 1/2 Terminated 3 enrolled University Hospitals Cleveland Medical Center

NaSingle-groupOpen-labelTreatment

Summary

This is an open label study of isotretinoin, a medication which is FDA approved for treatment of other conditions to determine initial safety in Alzheimer's disease.

Timeline

Start: 2012-04
Primary completion: 2014-08
Completion: 2014-08

Outcome

Outcome not reported

Stopped (Business): “Adverse events in 2/3 participants; study was halted but not restarted after this due to insufficnet funds as well”

Publications

Background Lee HP, Casadesus G, Zhu X, Lee HG, Perry G, Smith MA, Gustaw-Rothenberg K, Lerner A. All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease. Expert Rev Neurother. 2009 Nov;9(11):1615-21. doi: 10.1586/ern.09.86.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Isotretinoin	Other / unclassified	0.5 mg/kg	—